Search

This article explores a rare skin condition called cryptococcoid Sweet syndrome, which can be triggered by infection, cancer, or certain medications. The case discussed involves a patient who had previously used hydralazine and had a history of cocaine use. The article emphasizes the connection between hydralazine use and autoimmune disorders like Sweet syndrome. It also stresses the importance of distinguishing between true cryptococcosis and cryptococcoid Sweet syndrome, and calls for more research on this condition and its potential causes. [Extracted from the article]

Background: Transepidermal water loss (TEWL) and capacitance are used in atopic dermatitis (AD) trials to provide objective data on clinical change and response to therapy. Many barrier devices are costly, limiting their utility. GPSkin is a novel low‐cost, patient‐operable device that measures both TEWL and capacitance via smartphone application. Objective: This validation study investigated the correlation of GPSkin with the AquaFlux and Corneometer, and the reliability of these devices, in patients with AD. Methods: Fifty AD patients with varying disease severity performed self‐measurements with GPSkin, while investigators collected data with all 3 devices, on both nonlesional and lesional skin. Conclusion: GPSkin and AquaFlux demonstrated strong correlation for TEWL on nonlesional and lesional skin by Spearman's correlation (rs), independent of device user. For capacitance, GPSkin and the Corneometer showed moderate correlation when obtained by patients, yet a strong correlation when obtained by a clinician. Despite good correlation, GPSkin showed poor agreement with both the AquaFlux and Corneometer in Bland‐Altman plots. GPSkin underestimated both TEWL and capacitance. Overall, the devices had good test‐retest reliability. None of the devices could discriminate between AD severity states. While GPSkin marks an exciting advancement in barrier technology, further study is needed for validation on AD skin. [ABSTRACT FROM AUTHOR]

Five years after receiving her diagnoses of psoriasis and palmoplantar pustulosis, the patient developed psoriatic arthritis with enthesitis. With the advent of targeted pharmacological therapies, patients and physicians have found new hope for conditions previously recalcitrant to conventional therapies. We propose tofacitinib as a therapy for treatment-refractory patients. [Extracted from the article]

A case of a 15‐year‐old male patient with a 3‐year history of linear, segmental amyopathic dermatomyositis with calcinosis cutis is presented. The calcinosis was recalcitrant to treatment with topical steroids and hydroxychloroquine. Topical 10% sodium thiosulfate use for 8 weeks resulted in improvement. The use of topical sodium thiosulfate for patients in whom surgical extraction is not an option is detailed. [ABSTRACT FROM AUTHOR]

The article present a case study of a healthy 2-month-old, full-term boy with a lifelong history of intermittent skin dimpling of the bilateral legs, with occasional involvement of the abdomen and cheeks. It mentions examination of the patient's skin revealed bilateral skin rippling of his dorsolateral thighs with full resolution; and also mentions there was no evidence of associated erythema, overlying hypertrichosis, or other dermatologic findings.